A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Public ClinicalTrials.gov record NCT02034552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases
Study identification
- NCT ID
- NCT02034552
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 68 participants
Conditions and interventions
Conditions
Interventions
- Abiraterone acetate Drug
- Enzalutamide Drug
- Prednisone Drug
- Radium-223 dichloride (Xofigo, BAY88-8223) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2014
- Primary completion
- Jul 14, 2016
- Completion
- Jun 25, 2018
- Last update posted
- Jul 22, 2019
2014 – 2018
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | 85251 | — |
| Not listed | Tucson | Arizona | 85704 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | New Haven | Connecticut | 06520 | — |
| Not listed | Newark | Delaware | 19713 | — |
| Not listed | Washington D.C. | District of Columbia | 20007 | — |
| Not listed | Plantation | Florida | 33324 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | New Orleans | Louisiana | 70112 | — |
| Not listed | Shreveport | Louisiana | 71103 | — |
| Not listed | Rockville | Maryland | 20850 | — |
| Not listed | Detroit | Michigan | 48201 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Omaha | Nebraska | 68130 | — |
| Not listed | Syracuse | New York | 13210 | — |
| Not listed | The Bronx | New York | 10467-2490 | — |
| Not listed | Springfield | Oregon | 97477 | — |
| Not listed | Houston | Texas | 77027 | — |
| Not listed | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02034552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2019 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02034552 live on ClinicalTrials.gov.